Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

EP VanPuijenbroek*, PWG DuBufVereijken, PFMJ Spooren, JJ VanDoormaal

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

62 Citations (Scopus)

Abstract

The occurrence of rhabdomyolysis is one of the rare side-effects of the cholesterol-lowering agent simvastatin. During the use of lovastatin, an agent related to simvastatin, the risk of this side-effect might be increased when cyclosporin or gemfibrozil are used concomitantly. It is possible that this also applies for simvastatin. We present two patients who developed rhabdomyolysis during the concomitant use of simvastatin and gemfibrozil.

Original languageEnglish
Pages (from-to)403-404
Number of pages2
JournalJournal of Internal Medicine
Volume240
Issue number6
Publication statusPublished - Dec-1996

Keywords

  • simvastatin
  • gemfibrozil
  • adverse effect
  • rhabdomyolysis

Fingerprint

Dive into the research topics of 'Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil'. Together they form a unique fingerprint.

Cite this